Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aromasin "Suicide Inhibition" May Distinguish Drug From Other Inhibitors

Executive Summary

Aromasin's labeled "suicide inhibition" mechanism of action could be used by Pharmacia & Upjohn to distinguish the new drug, approved Oct. 21, from nonsteroidal aromatase inhibitors in the treatment of breast cancer.

You may also be interested in...

Searle Oncology Given Boost By Pending P&U Merger, Antibody Deal

Searle will create a platform for new oncologics development through a research collaboration with Cambridge Antibody Technology.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts